General Chapters – Dosage Forms – Visual Inspection Joint Subcommittee - Expert Advisor
Rockville, MD, United StatesYesterday
Key details
- Location
- Rockville, MD, United States
- Work style
- Onsite
- Level
- Senior
- Job type
- Full-time
- Function
- other
- Focus area
- other
- Posted
- Yesterday
Skills
caparisk assessmentroot cause analysisvisual inspection
About the role
2025-2030 Focus:
- USP <1790> modernization: updating visual inspection guidance, with a PF-ready draft targeted for early 2027.
- Particle classification: establishing consistent definitions for inherent, intrinsic, extrinsic, intended, and unintended particles, aligned with the Subvisible Particle team.
- Inspection methods & detectability: addressing visualization limits, threshold studies, manual/automated inspection, test sets, and difficult-to-inspect products.
- Sampling & acceptance criteria: AQL/acceptance sampling, PPQ sampling, small-batch sampling, and appropriate statistical approaches.
- Emerging/product-specific challenges: particularly cell & gene therapies, ophthalmics, opaque containers, biologics, and combination/device products.
- Packaging/device contributions: determining how particles introduced by packaging and delivery systems should be assessed and controlled.
- Particle identification & investigations: guidance around microscopy, FTIR, Raman, characterization, and root-cause analysis.
- Clinical risk: improving how particle type, size, source, route of administration, and patient population inform risk, while distinguishing visible-particle risk from subvisible-particle risk.
- Appearance testing vs. compendial visual inspection: clarifying when an appearance test can use USP <790>-based methods versus when a product can actually claim compliance with <790>.
- Compounding pharmacies: clarifying application of visual inspection expectations to 503B compounding and related settings.
- Visible/subvisible alignment: coordinating <1790> with the evolving <1788> framework so
USP uses a coherent approach to particles across the visible and subvisible continuum.
2025-2030 Key Issues:
- Modernizing USP <1790> and resolving outdated or ambiguous visual-inspection guidance.
- Particle classification: consistent treatment of inherent, intrinsic, extrinsic, intended, and unintended particles.
- Particle detectability: effects of size, type, contrast, formulation, container, and inspection conditions.
- Sampling & acceptance criteria: AQL, PPQ, destructive sampling, and especially small/ultra-small batches.
- Manual vs. automated inspection: method suitability, validation, test sets, and appropriate use of automated/semi-automated systems.
- Difficult/emerging products: cell & gene therapies, low-volume products, ophthalmics, opaque containers, and biologics with inherent particles.
- Particle identification & root-cause analysis: microscopy, FTIR, Raman, and other characterization approaches.
- Clinical relevance/risk: relating particle identity, size, source, administration route, and patient population to actual risk.
- Appearance vs. USP <790> inspection: clearly distinguishing general appearance testing from compendial compliance.
- Visible/subvisible alignment: ensuring the revised <1790> framework aligns with the Subvisible Expert Panel's <1788> work.
Required Expertise:
- Visual inspection science: manual, semi-automated, and automated inspection; detection probability and Knapp-type studies.
- Particle science & characterization: visible particle classification, morphology, microscopy, FTIR, Raman, and root-cause identification.
- Statistics & sampling: AQL, acceptance sampling, PPQ sampling, detection thresholds, and approaches for small batches.
- Biologics/formulation science: protein aggregates and inherent particles, including challenging or difficult-to-inspect products.
- Advanced modalities: cell & gene therapy and other low-volume or complex products where conventional inspection approaches may not readily apply.
- Packaging & device expertise: vials, syringes, stoppers, combination products, container-closure systems, and packaging-related particle generation.
- Clinical/toxicological risk assessment: translating particle size, identity, source, route of administration, and patient population into meaningful risk.
- Manufacturing & quality systems: inspection qualification/validation, defect investigations, trending, CAPA, process controls, and lifecycle management.
- Compendial/regulatory expertise: deep understanding of USP <790>, <1790>, related particulate-matter standards, and expectations for compendial compliance. The subcommittee's major current deliverable is modernization of <1790>.
How well do you match this job?
Skills
Experience
Level
Title
Location
Salary
Freshness
Similarity
Free account needed to apply or save. It takes a minute, and we'll bring you right back to this job.